Short answer
Mirum Pharmaceuticals, Inc. (MIRM) filed an 8-K current report with the SEC on September 28, 2026 reporting Item 8.01 (Other Events). FDA approved Atebrioz for FOP patients aged 12+, enabling U.S. commercialization expected in October 2026.
Mirum Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA approved Atebrioz for FOP patients aged 12+, enabling U.S. commercialization expected in October 2026
- Atebrioz reduced new HO volume by 3.2 cm³ versus a 24.6 cm³ increase with placebo at Week 24
- Phase 3 AZURE-1 brelovitug endpoint achieved: 56% and 45% response versus 0% delayed treatment
- AZURE-4 topline data expected Q4 2026, supporting a potential BLA filing in H1 2027 and launch in Q4 2027
- Management estimates annual revenue potential above $1 billion for brelovitug and above $200 million for Atebrioz
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mirum Pharmaceuticals, Inc. 8-K filings
Get the next MIRM 8-K as it lands
Follow MIRM for push alerts, or ask the research agent what this filing means.